NKGen Biotech announces publication of Phase 1 troculeucel trial results

NKGen Biotech (NKGN) announced the publication of results from the Company’s initial dose escalation Phase 1 clinical trial of troculeucel, an expanded autologous NK cell therapy, for the treatment of Alzheimer’s disease, AD, in the journal Alzheimer’s Research & Therapy, an international peer-reviewed journal with a translational research focus in AD and other neurodegenerative diseases. Highlights: The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse events following troculeucel therapy. Troculeucel therapy was well-tolerated and resulted in beneficial effects on protein aggregate levels and neuroinflammatory biomarkers in the cerebrospinal fluid, with decreases in pTau181 and GFAP appearing to be dose dependent. A larger trial with a higher dosing/duration has been initiated in the U.S. and is on-going.